Cargando…
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
Monoclonal antibodies (mAbs) targeting antigens expressed by plasma cells demonstrated major clinical activity in multiple myeloma patients and therefore became a new major class of drug for these patients. Elotuzumab is a humanized mAb targeting the cell surface signaling lymphocytic activation mol...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645600/ https://www.ncbi.nlm.nih.gov/pubmed/31410026 http://dx.doi.org/10.2147/OTT.S174640 |